ArticleBiologics : targets & therapy2026
Optimization of Recombinant Human Interferon-Gamma Expression and Purification in
Article in Biologics : targets & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recombinant human interferon gamma (rhIFN-γ) and monoclonal antibodies are promising biomolecules for improving clinical medicines worldwide due to their biomedical applications. However, most African countries lack established production protocols. Although Freund's Complete Adjuvant (FCA) has been widely used to enhance antibody production, it has been reported to cause adverse effects. This study aimed to optimize the expression and purification of rhIFNγ and develop an immunization protocol for producing optimal humoral responses using alternative adjuvants such as RIBI Immunochem (RIBI) adjuvant and Freund's Incomplete Adjuvant (FIA), with FCA as the standard. Methodology: The human interferon gamma (NM000619.3) sequence was retrieved from NCBI and sent to GenScript for codon optimization and construct synthesis. The constructs were transformed into Results: The study identified 0.6 mM of IPTG at 37°C and 250 rpm for 4 hours as the optimal conditions for rhIFNγ expression. Increasing imidazole concentration in wash and elution buffers enhanced rhIFNγ purity but reduced protein yield. Administration of 100 µg of rhIFNγ with RIBI adjuvant elicited a sufficient immune response, while higher concentrations of FCA and FIA increased side effects, indicating the need for lower adjuvant doses. Conclusion: Although FCA has been reported to produce high antibody titers with notable side effects, this study found no significant difference in antibody levels between mice immunized with 100 µg rhIFNγ mixed with FCA and the group immunized with 100 µg rhIFNγ plus RIBI adjuvant.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.